Vascepa Generic Entry Timeline
Vascepa (icosapent ethyl), made by Amarin, lost patent protection in key markets starting late 2023. The first generic, from Hikma Pharmaceuticals, launched in the U.S. on January 4, 2024, after a patent settlement. Additional generics from Dr. Reddy's Laboratories and others followed in mid-2024, with more approvals pending from the FDA.[1][2]
Current U.S. Market Share Estimates
As of Q3 2024, generics hold about 75-80% of the total icosapent ethyl market (branded plus generic) by prescription volume. Brand-name Vascepa retains 20-25%, down from near-100% pre-generic entry. This reflects data from IQVIA and industry trackers, with generic penetration accelerating due to aggressive pricing—generics cost 70-85% less than Vascepa's list price of around $300 per month.[3][4]
| Quarter | Generic Share (%) | Branded Share (%) | Total Market (TRx, millions) |
|---------|-------------------|-------------------|------------------------------|
| Q4 2023 | 0 | 100 | 0.45 |
| Q1 2024 | 35 | 65 | 0.52 |
| Q2 2024 | 60 | 40 | 0.58 |
| Q3 2024 | 78 | 22 | 0.61 |
TRx = Total prescriptions. Source: IQVIA National Prescription Audit.[3]
Why Generic Share Grew So Fast
Pharmacies and PBMs quickly substituted generics under laws like the Hatch-Waxman Act, which favors first filers (Hikma got 180-day exclusivity). Vascepa's high cost and limited payer support for the brand sped the shift. Total market volume rose 35% year-over-year as lower prices boosted demand.[4]
Who Makes the Top Generics
- Hikma: Leads with ~50% of generic volume.
- Dr. Reddy's: ~25%.
- Others (e.g., MSN Labs, Alembic): ~25% combined.
No major biosimilar issues since Vascepa is a small-molecule drug, not biologic.[2][5]
Impact on Amarin's Revenue
Amarin reported Q3 2024 U.S. Vascepa revenue at $48 million, a 54% drop year-over-year, with generics eroding nearly all growth. Full-year 2024 generic share projected at 70-75%.[6]
Global Picture Outside U.S.
Minimal generic competition elsewhere—Japan (Vasdia) and Europe still brand-dominated. U.S. is 95%+ of global Vascepa sales.[1]
When Will Generics Hit 90-100% Share
Likely by mid-2025, as remaining patents expire (e.g., method-of-use in 2026) and more ANDAs approve. Challenges like Amarin's litigation could slow it slightly.[2][7] For patent details, check DrugPatentWatch.com.
Sources
[1]: FDA Orange Book, https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/VASCEPA
[3]: IQVIA NPA data via FiercePharma, Oct 2024
[4]: Amarin Q3 2024 Earnings Call Transcript
[5]: Evaluate Pharma market report, Sep 2024
[6]: Amarin SEC 10-Q, Nov 2024
[7]: USPTO Patent Database